Skip to main content
2024 CNSF Congress Main banner
Neuro|News Annual Edition
Final Program


Calendar-of-Events
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Evaluation

UofT NSX 100 Years

International Consortium on Meningiomas (ICOM) – Part 2

Tuesday, May 21, 2024
1:00 PM – 4:15 PM EST
Location:MM: NWT
CE: 3.25

Audience:

Adult Neurologist, Neurosurgeon, Neuroradiologist, Neurophysiologist, Resident, Fellow, Nurses with interest in topic

Learning Level:

Basic (Resident, New Information), Intermediate (Practicing Physician), Advanced (Special Interest, Higher Level Discussion)

Learning Format:

Discussion group/peer exchange/user groups, Lecture/plenary method

CanMEDs Roles:

Medical Expert, Scholar, Communicator, Collaborator, Leader, Professional

The International Consortium on Meningiomas (ICOM) is hosting a scientific day on Tuesday, May 21 as part of CNSF. Led by Dr. Gelareh Zadeh, this consortium was formed to increase awareness for this understudied disease and conduct cutting-edge meningioma research through international and multidisciplinary collaboration. This meeting’s program will feature updates on ongoing collaborative research as well as a practical overview of modern meningioma management, with themes including surgical management, biomarkers, clinical trials updates and more. We will also host a molecular tumour board where complex cases are reviewed by an expert multidisciplinary panel with opportunity for audience involvement. These sessions will be highly relevant to anyone involved in meningioma research or clinical care and all are welcome to attend.

Learn more on ICOM https://www.meningiomaconsortium.com .

Scientific Committee: Alex Landry, Farshad Nassiri, Justin Wang, Gelareh Zadeh

For more details visit UofT Division of Neurosurgery: Celebrating 100 Years and Beyond (uoftnsx100years.ca)

Learning Objectives:

  • Understand the Current Landscape of Meningioma Research and Treatment: Attendees will gain comprehensive insights into the latest epidemiological trends, molecular pathology, and WHO classifications of meningiomas. This includes understanding the impact of genetic and molecular findings on the diagnosis, treatment planning, and prognosis of meningioma patients.
  • Learn about Surgical and Therapeutic Innovations in Meningioma Management: Participants will explore the advancements in surgical techniques, including open and endoscopic approaches, and the role of preoperative embolization. Additionally, updates on clinical trials, theranostics, and innovative treatment strategies in both European and North American contexts will be discussed. The objective is to enhance knowledge on how these innovations can improve patient outcomes and expand treatment options.
  • Evaluate Quality of Life and Survivorship Issues for Meningioma Patients: The conference aims to highlight the importance of quality of life considerations in the treatment and management of meningioma patients. This includes discussions on the challenges faced by special populations, the impact of treatments on quality of life, and strategies for addressing these issues in clinical practice. Attendees will learn about the latest research and practical approaches to support meningioma survivors in their recovery and long-term well-being.

Presentations:

  • 1:00 PM – 2:00 PM EST
    Molecular Tumor Board Moderators: Farshad Nassiri, Susan Short

    Co-Chair: Farshad Nassiri

    Co-Chair: Susan Short

    Speaker: Michael Cusimano

    Speaker: Kate Drummond

    Speaker: Eva Galanis

    Speaker: Andrew Gao

    Speaker: Joerg-Christian Tonn

    Speaker: Derek S. Tsang

  • 2:00 PM – 2:15 PM EST
    DOTATATE-PET and Theranostics of Meningioma: European Update

    Speaker: Joerg-Christian Tonn

  • 2:15 PM – 2:30 PM EST
    Clinical Trial Design of Theranostics of Meningioma - North American Update

    Speaker: Erik Sulman

  • 2:30 PM – 2:45 PM EST
    Alliance Trials and Opportunities: The Role of Umbrella Trials in Meningioma

    Speaker: Eva Galanis

  • 2:45 PM – 3:00 PM EST
    Radiation versus Observation for Atypical Meningioma: update from the ROAM/EORTC1308 trial

    Speaker: Michael Jenkinson

  • 3:00 PM – 3:15 PM EST
    Evaluating Immunohistochemical Surrogates for Meningioma Molecular Subtypes

    Speaker: P.J. Cimino

  • 3:15 PM – 3:30 PM EST
    Outcomes in Grade 3 Meniningioma

    Speaker: Alexander Rebchuk

  • 3:30 PM – 3:45 PM EST
    Updates on Molecular Pathology of Meningioma/WHO Grading

    Speaker: Stephen Yip

  • 3:45 PM – 4:00 PM EST
    Mutation Landscape of Meningioma Grade Progression

    Speaker: Kate Drummond

  • 4:00 PM – 4:15 PM EST
    cIMPACT update

    Speaker: Felix Sahm

  • 4:15 PM EST
    Discussion/ Closing Remarks

    Speaker: Gelareh Zadeh